Genomtec S.A. (WAR:GMT) — Stock Price
Genomtec S.A. (WAR:GMT) is currently trading at zł4.09 PLN, up 0.00% today. Over the past 52 weeks, shares have ranged between zł3.45 and zł7.07. This page tracks Genomtec S.A.'s live share price on the WAR exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see Genomtec S.A. stock valuation.
Genomtec S.A. (GMT) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Genomtec S.A.'s daily closing share price and trading volume on the WAR exchange over the past year, giving a clear view of recent price momentum and liquidity.
Genomtec S.A. Income Statement — Revenue, Profit & Earnings by Year
Genomtec S.A.'s annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Revenue | zł1.00K | zł1.00K | zł40.00K | zł219.00K | zł20.00K |
| Cost of Revenue | zł2.33 Million | zł794.00K | zł857.00K | zł595.00K | zł248.00K |
| Gross Profit | zł1.00K | zł-793.00K | zł-817.00K | zł-376.00K | zł-228.00K |
| Research & Development | zł4.31 Million | zł793.00K | zł3.24 Million | zł4.83 Million | zł3.42 Million |
| SG&A | zł4.15 Million | zł9.43 Million | zł8.57 Million | zł5.15 Million | zł1.93 Million |
| Total Operating Expenses | zł11.06 Million | zł7.93 Million | zł11.14 Million | zł10.16 Million | zł14.25 Million |
| Operating Income | zł-11.05 Million | zł-8.73 Million | zł-11.95 Million | zł-10.54 Million | zł-14.48 Million |
| EBITDA | zł-8.72 Million | zł-7.76 Million | zł-11.06 Million | zł-6.58 Million | zł-10.67 Million |
| EBIT | zł-11.05 Million | zł-8.91 Million | zł-11.49 Million | zł-7.08 Million | zł-10.92 Million |
| Interest Expense | zł134.00K | zł236.00K | zł292.00K | zł28.00K | zł18.00K |
| Income Before Tax | zł-11.19 Million | zł-9.03 Million | zł-11.88 Million | zł-7.11 Million | zł-10.94 Million |
| Income Tax Expense | zł20.00K | zł-18.00K | zł46.00K | zł5.00K | zł4.00K |
| Net Income | zł-11.21 Million | zł-9.01 Million | zł-11.93 Million | zł-7.12 Million | zł-10.94 Million |
Genomtec S.A. Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Genomtec S.A.'s financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Assets | zł17.04 Million | zł15.97 Million | zł11.80 Million | zł4.22 Million | zł9.37 Million |
| Total Current Assets | zł8.49 Million | zł6.64 Million | zł4.99 Million | zł2.25 Million | zł8.08 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | — | — | — | — | — |
| Net Receivables | zł1.75 Million | zł2.00K | zł685.00K | zł164.00K | zł167.00K |
| Inventory | zł0.00 | zł0.00 | zł105.00K | zł196.00K | zł113.00K |
| Property, Plant & Equipment | — | — | — | zł1.91 Million | zł1.24 Million |
| Goodwill | — | — | — | — | — |
| Total Liabilities | zł9.44 Million | zł7.67 Million | zł6.87 Million | zł3.48 Million | zł1.80 Million |
| Total Current Liabilities | zł5.48 Million | zł3.14 Million | zł2.32 Million | zł2.57 Million | zł1.11 Million |
| Long-term Debt | — | — | — | — | — |
| Net Debt | zł-3.96 Million | zł-2.18 Million | zł-1.86 Million | zł363.00K | zł-6.27 Million |
| Total Stockholder Equity | zł7.60 Million | zł8.30 Million | zł4.89 Million | zł723.00K | zł7.57 Million |
| Retained Earnings | zł-51.31 Million | zł-40.10 Million | zł-31.09 Million | zł-19.16 Million | zł-12.04 Million |
Genomtec S.A. Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Genomtec S.A. generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Cash Flow | zł-6.72 Million | zł-7.95 Million | zł-3.79 Million | zł-5.53 Million | zł-2.52 Million |
| Capital Expenditures | zł59.00K | zł3.53 Million | zł4.33 Million | zł213.00K | zł127.00K |
| Free Cash Flow | zł-6.78 Million | zł-11.48 Million | zł-8.12 Million | zł-5.74 Million | zł-2.64 Million |
| Investing Cash Flow | zł-380.00K | zł-3.80 Million | zł-4.33 Million | zł-213.00K | zł-79.00K |
| Financing Cash Flow | zł9.62 Million | zł11.80 Million | zł10.89 Million | zł-196.00K | zł8.47 Million |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | zł0.00 | zł0.00 | zł4.83 Million | — | — |
| Depreciation | zł2.33 Million | zł1.16 Million | zł436.00K | zł504.00K | zł244.00K |
| Change in Cash | zł2.53 Million | zł42.00K | zł2.76 Million | zł-5.92 Million | zł5.88 Million |
Genomtec S.A. Earnings History — EPS Actual vs. Analyst Estimates
Track Genomtec S.A.'s quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Mar 31, 2026 | -0.15 | — | — |
| Dec 31, 2025 | -0.09 | — | — |
| Sep 30, 2025 | -0.17 | — | — |
| Jun 30, 2025 | -0.23 | — | — |
| Mar 31, 2025 | -0.22 | — | — |
| Dec 31, 2024 | -0.14 | — | — |
| Sep 30, 2024 | -0.25 | — | — |
| Jun 30, 2024 | -0.25 | — | — |